Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22258127 | 0.78 | MCL1 (0.60) | MCL1IDO1SRD5A2SLC9A1CTSL | |
| SCHEMBL15979629 | 0.77 | MCL1 (0.64) | MCL1IDO1SLC9A1MEN1NPC1 | |
| SCHEMBL13783988 | 0.75 | MCL1 (0.54) | MCL1IDO1SLC9A1MEN1NPC1 | |
| SCHEMBL14380392 | 0.75 | MCL1 (0.54) | MCL1IDO1SLC9A1NPC1RAB9A | |
| SCHEMBL27467673 | 0.75 | MCL1 (0.74) | MCL1IDO1SLC9A1MEN1NPC1 | |
| SCHEMBL13783939 | 0.74 | HDAC1 (0.74) | MCL1IDO1SLC9A1HDAC1HDAC2 | |
| SCHEMBL6488590 | 0.73 | TDP1 (0.61) | NPC1RAB9AKMT2AHDAC1HDAC2 | |
| SCHEMBL10031558 | 0.73 | MCL1 (0.67) | MCL1IDO1SLC9A1MEN1NPC1 | |
| SCHEMBL17529434 | 0.73 | MCL1 (0.57) | MCL1IDO1SLC9A1MEN1NPC1 | |
| SCHEMBL543078 | 0.72 | ALDH1A1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070591-A1 | Indole derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1464645-A1 | INDOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070591-A1 | Indole derivative | TPH1, IDO1, RBX1 | MCL1 1979/4885IDO1 2/4885SRD5A2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.